QurientPipeline


 

Pipeline

Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.

Discovery Candidate Pre-Clinical Phase 1 Phase 2 Phase 3
Anti
Cancer
Axl/Mer/CSF1R
Inhibitor
(Q702)
Immuno
Oncology
Drug Resistant
NSCLC
selective CDK7 inhibitor
(Q901)
Solid
Tumor
Antibiotics Cyt bc1 Inhibitor
(Telacebec,
Q203)
Drug Resistant
Tuberculosis
COVID-19
anti-inflammation
Anti
Inflammation
Topical 5LO
Inhibitor
(Q301)
Atopic
Dermatitis
Oral
5LO Inhibitor
Asthma
Candidate Pre-Clinical Phase 1 Phase 2
Axl/Mer/
CSF1R
Inhibitor
(Q702)
Immuno
Oncology
Drug
Resistant
NSCLC
Selective
CDK7
Inhibitor
(Q901)
Solid
Tumor
Cytbc1
Inhibitor
(Telacebec,
Q203)
Drug
Resistant
Tuberculosis
COVID-19
anti-inflammation
Topical
5LO Inhibitor
(Q301)
Atopic
Dermatitis
Oral
5LO
Inhibitor
Asthma
information for download file